Clovis Oncology Inc CLVSQ

Healthcare Biotechnology

Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR a/ß) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

PINL:CLVSQ - Post by User

Clovis Oncology Inc

Bullboard Posts

Post by wsnews4investoron May 15, 2015 8:42am

278 Views

Post# 23731836

Top gainers of Healthcare Sector stocks: CLVS, CRME, ACRX

HealthCare sector showed uptrend on Thursday and in this article we discuss top gainers of HealthCare sectors and disclose their news. Top gainers include Clovis Oncology (NASDAQ:CLVS), CARDIOME PHARMA (NASDAQ:CRME), AcelRx Pharmaceuticals (NASDAQ:ACRX).

Three Healthcare stocks rose broadly on Wall Street so far on Thursday, with the sector seeing generally rise of +1.38%.

Read more at www.wsnews4investors.com/boost-performance-of-healthcare-sector/

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features